"As the first combined COVID-19/influenza vaccine, mCombriax provides people with the option of having a single shot to protect against both illnesses. The shot works like any other vaccine, effectively prepping the human body to defend itself against foreign infection, with the messenger RNA contained within giving blueprints to the body to make proteins to help stave off various seasonal flu viruses, and SARS-CoV-2."
"The CHMP's positive opinion represents an important milestone for respiratory virus vaccination and for Moderna, with the introduction of the world's first flu plus COVID combination vaccine. Combination vaccines have the potential to simplify vaccination and support improved health outcomes."
"The European Medicines Agency, the regulator granting the recommendation, said that the messenger RNA vaccine should help protect people aged 50 years and older against COVID-19 and seasonal influenza (flu). Next, the European Commission would need to ratify the recommendation to open it up for widespread use."
Moderna's mCombriax vaccine received a positive opinion from the European Medicines Agency, recommending authorization for people aged 50 and older. The messenger RNA vaccine provides protection against both COVID-19 and seasonal influenza through a single shot. mCombriax represents the first combined COVID-19/influenza vaccine, simplifying vaccination by eliminating the need for separate shots. The European Commission must ratify this recommendation for widespread EU use. Moderna previously applied for FDA clearance in the United States in 2024, but the FDA requested additional supplemental data, complicating the U.S. approval timeline.
#combination-vaccine #mrna-technology #european-regulatory-approval #covid-19-and-influenza-protection #vaccine-authorization
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]